glucose, (beta-d)-isomer has been researched along with Non-alcoholic Fatty Liver Disease in 94 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 40 (42.55) | 24.3611 |
| 2020's | 54 (57.45) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, L; Ding, Y; Fan, Y; Fatima, M; Gao, J; Han, T; Wang, C; Zhang, Y | 1 |
| Aishima, S; Anzai, K; Eguchi, Y; Fujii, H; Hyogo, H; Imajo, K; Isoda, H; Kage, M; Kawaguchi, A; Kawanaka, M; Kessoku, T; Kitajima, Y; Kubotsu, Y; Kurai, O; Nakajima, A; Nakajima, T; Nonaka, M; Oeda, S; Ono, M; Tajiri, R; Takahashi, H; Takamori, A; Tanaka, K; Yoneda, M | 1 |
| Haluzik, M; Hüttl, M; Malinska, H; Markova, I; Miklankova, D; Poruba, M; Vaněčkova, I; Zapletalova, I | 1 |
| Choi, SE; Han, SJ; Heo, YJ; Jeon, JY; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Lee, N | 1 |
| Abe, H; Goto, R; Kamimura, H; Kamimura, K; Kimura, A; Morita, S; Oda, C; Ohkoshi-Yamada, M; Owaki, T; Sakai, N; Sakamaki, A; Shibata, O; Shinagawa-Kobayashi, Y; Terai, S; Yokoo, T | 1 |
| Chen, YF; Liu, RJ; Shne, ZL; Xu, JM; Ye, F; Yuan, MQ; Zeng, QQ; Zhu, L; Zhu, YX; Zou, J | 1 |
| Inzucchi, SE; Kahl, S; Ofstad, AP; Roden, M; Sattar, N; Schüler, E; Wanner, C; Zinman, B | 1 |
| Fujihara, S; Fujita, K; Haba, R; Himoto, T; Iwama, H; Masaki, T; Morishita, A; Nakahara, M; Nishiyama, A; Okano, K; Ono, M; Oura, K; Shi, T; Tadokoro, T; Takuma, K; Tani, J | 1 |
| Ge, J; He, K; Jing, Z; Li, J; Sun, J; Xi, W | 1 |
| Aburatani, H; Anai, M; Asahiyama, M; Fruchart, JC; Fruchart-Najib, J; Kamiya, W; Kodama, T; Matsumura, Y; Murakami, K; Osawa, T; Sakai, J; Sasaki, Y; Takizawa, T; Tanaka, T; Yano, W | 1 |
| Liu, X; Wang, X; Zhang, H; Zhang, Y | 1 |
| Deng, C; Gu, Y; He, Y; Shi, J; Sun, L; Yang, L | 1 |
| Bedin, C; Rosso, N; Saccani, A; Salvoza, N; Tiribelli, C | 1 |
| Anzai, K; Takahashi, H | 1 |
| Honda, Y; Imajo, K; Kessoku, T; Kirikoshi, H; Kobayashi, T; Nakajima, A; Nogami, A; Ogawa, Y; Saito, S; Taguri, M; Yoneda, M | 1 |
| de Knegt, RJ; van Kleef, LA | 1 |
| Albanese, C; Choos, END; Ecelbarger, CM; Jones, BA; Knoer, G; Kurtz, R; Lee, Y; Levi, M; Libby, A; Lo Cascio, JN; McCormack, M; Myakala, K; Nguyen, G; Ranjit, S; Rodriguez, O; Rosenberg, AZ; Shepard, BD; Wang, X | 1 |
| Chen, S; Luo, J; Piao, C; Wang, L; Zhao, X | 1 |
| Arai, K; Goto, H; Harada, K; Honda, M; Iida, N; Kaneko, S; Kita, Y; Mizukoshi, E; Nakamura, H; Nakano, Y; Takamura, T; Takata, N; Takeshita, Y; Tanaka, T; Tsujiguchi, H; Yamashita, T | 1 |
| Fang, QH; Li, CJ; Lin, JN; Niu, WY; Shen, QL; Shi, YX; Sun, B; Wang, Y; Xin, Q; Zhang, S | 1 |
| Dun, Y; Li, D; Li, H; Liu, J; Liu, S; Qiu, L; Ripley-Gonzalez, JW; You, B; Zhang, J | 1 |
| Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A | 1 |
| Liang, Y; Liu, X; Lu, L; Qu, B; Zhang, C; Zheng, K | 1 |
| Hao, R; Li, Z; Shan, S; Sun, Y; Yang, D; Zhang, H | 1 |
| Tang, X; Wang, X; Yang, D; Zhang, H | 1 |
| Agarwal, N; Khan, P; Parveen, R; Pathak, M; Saha, N | 1 |
| Cui, C; Guo, X; Liu, J; Qiao, Q; Shi, M; Wang, J; Wang, Q; Wang, W; Wang, Y; Xu, J; Zhang, C; Zhang, H; Zhang, X | 1 |
| Barbosa-da-Silva, S; Petito-da-Silva, TI; Souza-Mello, V | 1 |
| Goto, R; Kamimura, K; Kimura, A; Ko, M; Nagoya, T; Nishina, H; Niwa, Y; Sakai, N; Shinagawa-Kobayashi, Y; Terai, S | 1 |
| Ferrannini, E; Gastaldelli, A; Guja, C; Han, J; Hardy, E; Jabbour, SA; Repetto, E | 1 |
| Tahara, A; Takasu, T | 1 |
| Fukuda, S; Hosokawa, K; Ida, A; Isomoto, H; Iyama, T; Kanda, T; Koda, M; Mae, Y; Matono, T; Sugihara, T; Takata, T; Taniguchi, S; Yamamoto, M | 1 |
| Hu, Y; Li, H; Tian, H; Xi, Y; Xin, X | 1 |
| Eguchi, Y; Fujii, H; Hyogo, H; Imajo, K; Jsg-Nafld, JSGON; Kamada, Y; Kawaguchi, T; Kawanaka, M; Koseki, M; Nakajima, A; Nozaki, Y; Okanoue, T; Ono, M; Sumida, Y; Takahashi, H; Tokushige, K; Yoneda, M; Yoshida, Y | 1 |
| Fushimi, Y; Hirata, Y; Hirukawa, H; Irie, S; Kaku, K; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakamura, Y; Nakanishi, S; Nakashima, K; Nishioka, M; Obata, A; Sanada, J; Shimoda, M; Tanabe, A; Tatsumi, F | 1 |
| Chen, M; Du, X; Fang, Z; Li, X; Liu, G; Loor, JJ; Peng, Z; Shen, T; Shi, Z; Shui, G; Song, Y; Wang, H; Wang, X; Wang, Z; Zhu, Y | 1 |
| Dai, XY; Gong, LH; Hu, NH; Li, YX; Peng, C; Wang, C; Yu, LY | 1 |
| Attia, SL; Mouzaki, M; Softic, S | 1 |
| Ebrahim, TM; ElMahdy, MK; Helal, MG | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Ismail-Beigi, F; Khamseh, ME; Malek, M; Reza Babaei, M; Sohrabi, M; Taheri, H; Zamani, F | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kameda, H; Kurihara, Y; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Takase, T; Taneda, S; Yamamoto, K | 1 |
| Lefor, AK; Ogura, M; Shinozaki, S; Tahara, T | 1 |
| Chen, D; Guo, Y; Jiang, G; Li, W; Liu, C; Liu, J | 1 |
| Chatzigeorgiou, A; Cholongitas, E; Chrysavgis, L; Papatheodoridi, AM | 1 |
| Nakamoto, K; Tsubakimoto, M; Yabiku, K | 1 |
| Honda, Y; Imajo, K; Iwasaki, T; Kessoku, T; Kirikoshi, H; Kobayashi, T; Kurihashi, T; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Taguri, M; Yamanaka, T; Yoneda, M | 1 |
| Chen, L; Cheng, Y; Fang, T; Han, L; Li, T; Liu, X; Meng, Z; Sun, B | 1 |
| Tahara, A | 1 |
| Aso, Y; Iijima, T; Jojima, T; Kato, K; Niitani, T; Sagara, M; Tomaru, T; Usui, I | 1 |
| Enomoto, A; Fujishiro, M; Ishigami, M; Ito, A; Itoh, M; Ochi, K; Ogawa, Y; Ogi, T; Ono, K; Sawada, M; Shiraki, Y; Suganami, T; Tanaka, M; Watanabe, A; Yoshioka, N | 1 |
| Buranapin, S; Chattipakorn, N; Euathrongchit, J; Leerapun, A; Phrommintikul, A; Phrueksotsai, S; Pinyopornpanish, K; Thongsawat, S | 1 |
| Chrysafi, P; Feigh, M; Mantzoros, CS; Perakakis, N; Veidal, SS | 1 |
| Chen, Y; Ding, Y; Luo, J; Niu, Y; Sun, P; Wang, Y; Xie, W; Xu, N; Zhang, Y | 1 |
| Hu, M; Huang, X; Qi, Z; Shi, H; Wang, X; Wu, Y; Xu, H; Zhang, D; Zhang, Y | 1 |
| Ding, Y; Fang, Q; Hu, S; Liang, Y; Liu, Z; Tian, S; Wan, J; Yang, D; Yang, L; Zhang, Y | 1 |
| Guo, J; Guo, Y; Han, X; Huang, W; Huang, Y; Jin, W; Liang, C; Liu, G; Liu, X; Ma, T; Meng, M; Ren, C; Sun, X; You, Y; Yuan, X; Zhan, J; Zhang, Q | 1 |
| Huang, X; Kobayashi, Y; Koike, K; Kojima-Yuasa, A; Li, W; Shirahata, T; Xu, M; Yuasa, I | 1 |
| Akiyama, Y; Inoue, K; Inukai, K; Ito, D; Morimoto, Y; Noda, M; Saito, D; Shimada, A; Shimizu, S; Yanagisawa, M | 1 |
| Fujimori, T; Ichikawa, K; Irahara, A; Kimata, K; Koketsu, Y; Nakano, A; Senda, E; Sumida, Y; Takata, E; Takeda, A; Yamada, H | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Bansal, B; Choudhary, NS; Farooqui, KJ; Gill, HK; Jevalikar, G; Kaur, P; Krishan, S; Kuchay, MS; Mishra, SK; Mithal, A; Singh, MK; Wasir, JS | 1 |
| Huang, Y; Jiang, R; Jiang, X; Ling, W; Pang, N; Pei, L; Qiu, Y; Wan, T; Wang, S; Yang, L; Ye, M; Zhang, Z; Zhou, Y | 1 |
| Eriksson, JW; Forsberg, GB; Jansson, PA; Johansson, L; Kvarnström, M; Lind, L; Lundkvist, P; Miliotis, T; Moris, L; Oscarsson, J; Risérus, U | 1 |
| Bai, M; Cheng, YX; Li, YC; Qiao, JY; Shen, JD; Wang, BY | 1 |
| Marx, N; Wanner, C | 1 |
| Bian, F; Chen, L; Jin, S; Li, W; Wang, Q; Wu, D; Xing, S; Yang, X; Zheng, T | 1 |
| Li, HS | 1 |
| Aso, Y; Hiraishi, H; Iijima, M; Iijima, T; Jojima, T; Kato, K; Murohisa, T; Shimizu, M; Suzuki, K; Takekawa, H; Usui, I | 1 |
| Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K; Uno, S | 1 |
| Chan, WK; Lai, LL; Mahadeva, S; Nik Mustapha, NR; Vethakkan, SR | 1 |
| Aso, Y; Iijima, T; Jojima, T; Kato, K; Kishi, H; Maejima, Y; Sakurai, S; Shimizu, M; Shimomura, K; Usui, I | 1 |
| Khan, RS; Newsome, PN | 1 |
| Hua, YQ; Peng, Y; Xu, J; Xu, XL; Zeng, Y | 1 |
| Chan, CS; Chan, H; Chan, MTV; Chen, X; Gin, T; Ho, IHT; Ho, J; Hu, W; Kou, S; Liu, X; Sun, X; Tian, Y; Wong, SH; Wu, WKK; Yu, J; Zhang, L; Zhang, X | 1 |
| Abe, S; Goto, R; Inoue, R; Kamimura, H; Kamimura, K; Ko, M; Nagoya, T; Nishina, H; Niwa, Y; Ogawa, K; Sakai, N; Sakamaki, A; Shinagawa-Kobayashi, Y; Terai, S; Yokoo, T | 1 |
| Ahmad, O; Cheng, L; Deng, Y; Li, M; Ma, K; Shang, J; Wang, B; Yang, L; Yang, Y; Zhao, J; Zhou, Q | 1 |
| Atsumi, T; Cho, KY; Hatanaka, KC; Kameda, H; Kitao, N; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Takagi, R; Takahashi, K; Terauchi, Y | 1 |
| Katsiki, N; Mantzoros, C; Perakakis, N | 1 |
| Guo, H; Jiang, X; Liu, G; Tang, X; Zhang, P | 1 |
| Han, N; Liu, Z; Xiao, B; Yin, J; Zhou, C; Zhou, J | 1 |
| Hayashizaki-Someya, Y; Koide, K; Kurosaki, E; Mitori, H; Takakura, S; Takasu, T; Yamazaki, S | 1 |
| Yang, B; Yu, B; Zhang, L | 1 |
| Gu, W; Lin, P; Lu, J; Wang, Y; Yu, J; Zhao, R | 1 |
| Bhaswant, M; Brown, L; Fanning, K; Mathai, ML; Netzel, M; Panchal, SK | 1 |
| Jiang, JD; Jiang, WX; Kong, WJ; Li, Z; Qu, LL; Yu, B | 1 |
| Fujita, K; Honda, Y; Imajo, K; Kato, S; Kato, T; Kessoku, T; Mawatari, H; Nakajima, A; Ogawa, Y; Saito, S; Tomeno, W; Yoneda, M | 1 |
| Isogawa, A; Ohki, T; Tagawa, K; Toda, N | 1 |
| Furuke, S; Kanno, K; Komiya, C; Miyachi, Y; Ogawa, Y; Shiba, K; Shimazu, N; Tsuchiya, K; Yamaguchi, S | 1 |
| Dai, N; Guan, LL; Wang, HF; Yang, ZR; Zuo, TC | 1 |
| Chu, L; Dai, J; Gao, Y; Li, J; Liu, H; Liu, W; Ma, Z; Yi, J; Zhang, Y | 1 |
| Atsumi, T; Miyoshi, H; Nakamura, A; Takase, T; Yamamoto, C | 1 |
| Chu, L; Gao, Y; Li, J; Liu, H; Ma, Z; Wang, W; Yao, W; Yi, J | 1 |
| Tan, Y; Yao, F; Zhang, J; Zhang, Q | 1 |
13 review(s) available for glucose, (beta-d)-isomer and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Topics: Adult; Benzhydryl Compounds; Cholesterol, HDL; Glucosides; Humans; Non-alcoholic Fatty Liver Disease | 2022 |
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Topics: Benzhydryl Compounds; Glucosides; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease | 2022 |
Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Cholesterol, LDL; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic | 2022 |
Pharmacological effects of polydatin in the treatment of metabolic diseases: A review.
Topics: AMP-Activated Protein Kinases; Atherosclerosis; Diabetes Mellitus; Glucosides; Gout; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Phosphatidylinositol 3-Kinases; Quality of Life; Stilbenes | 2022 |
Salidroside in the Treatment of NAFLD/NASH.
Topics: Fibrosis; Glucosides; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2022 |
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Glucosides; Humans; Liver; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic | 2022 |
Impact of tofogliflozin on hepatic outcomes: a systematic review.
Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Glucosides; Humans; Liver; Non-alcoholic Fatty Liver Disease | 2023 |
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Japan; Non-alcoholic Fatty Liver Disease | 2020 |
Evolving Role for Pharmacotherapy in NAFLD/NASH.
Topics: Adult; Benzhydryl Compounds; Chenodeoxycholic Acid; Child; Clinical Trials, Phase III as Topic; Fibroblast Growth Factors; Glucosides; Humans; Imidazoles; Isobutyrates; Liraglutide; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Oxazoles; Polyethylene Glycols; Pyridazines; Pyrimidines; Severity of Illness Index; Sulfoxides; Treatment Outcome; Uracil | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
18 trial(s) available for glucose, (beta-d)-isomer and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2022 |
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
Topics: Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2022 |
Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prospective Studies | 2022 |
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Sulfonylurea Compounds | 2022 |
Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Interleukin-6; Liver; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Tumor Necrosis Factor-alpha | 2023 |
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Exenatide; Fibrosis; Glucosides; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Prospective Studies | 2020 |
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Liver; Non-alcoholic Fatty Liver Disease; Prospective Studies | 2020 |
Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Triglycerides; Waist Circumference; Weight Loss | 2021 |
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Japan; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prospective Studies | 2021 |
Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Adiponectin; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Non-alcoholic Fatty Liver Disease | 2021 |
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Topics: Adipose Tissue; Adiposity; Adult; Alanine Transaminase; Aspartate Aminotransferases; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2018 |
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Carboxylic Acids; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Acids; Female; Glucose; Glucosides; Hepatocytes; Humans; Inflammation; Lipid Metabolism; Liver Function Tests; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Sweden | 2018 |
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Elasticity Imaging Techniques; Female; Glucosides; Humans; Lipid Metabolism; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; gamma-Glutamyltransferase; Glucosides; Hepatitis; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Fat; Weight Loss | 2019 |
64 other study(ies) available for glucose, (beta-d)-isomer and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice.
Topics: Adiposity; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucosides; Insulin Resistance; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia.
Topics: Animals; Benzhydryl Compounds; Cytochrome P-450 Enzyme System; Disease Models, Animal; Disease Progression; Glucosides; Hyperglycemia; Hyperlipoproteinemia Type IV; Inflammation Mediators; Insulin Resistance; Lipid Metabolism; Liver; Male; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Prediabetic State; Rats; Rats, Mutant Strains; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.
Topics: Amino Acids; Animals; Benzhydryl Compounds; Choline; Cytokines; Diet, High-Fat; Disease Models, Animal; Disease Progression; Glucosides; Inflammation; Inflammation Mediators; JNK Mitogen-Activated Protein Kinases; Liver; Macrophage Activation; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phosphorylation; Piperidones; Protective Agents; Pyrimidines | 2022 |
Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model.
Topics: Animal Fins; Animals; Animals, Genetically Modified; Benzhydryl Compounds; Benzoxazoles; Butyrates; Diet, High-Fat; Disease Models, Animal; Exome Sequencing; Gene Ontology; Glucosides; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Non-alcoholic Fatty Liver Disease; Oryzias; PPAR alpha; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Sodium-Glucose Transporter 2 Inhibitors; Transcriptome | 2022 |
Luteoloside Ameliorates Palmitic Acid-Induced in Vitro Model of Non-alcoholic Fatty Liver Disease via Activating STAT3-Triggered Hepatocyte Regeneration.
Topics: Glucosides; Hepatocytes; Humans; Liver; Luteolin; Non-alcoholic Fatty Liver Disease; Palmitic Acid; STAT3 Transcription Factor | 2021 |
Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Fasting; Gene Expression Profiling; Gene Expression Regulation; Glucosides; Hepatocytes; Hypoglycemic Agents; Interleukin-1beta; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Non-alcoholic Fatty Liver Disease; Signal Transduction; Streptozocin; Superoxide Dismutase; Thiophenes; Tumor Necrosis Factor-alpha | 2022 |
Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.
Topics: Animals; Benzhydryl Compounds; Benzoxazoles; Butyrates; Carcinoma, Hepatocellular; Glucosides; Liver Neoplasms; Mice; Non-alcoholic Fatty Liver Disease; PPAR alpha; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2022 |
The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH).
Topics: Collagen; Fatty Acids, Nonesterified; Glucosides; Humans; Liver; Non-alcoholic Fatty Liver Disease; Phenols; Reactive Oxygen Species; Tumor Necrosis Factor-alpha | 2022 |
Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".
Topics: Diabetes Mellitus; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Thiophenes | 2022 |
Reply to: "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".
Topics: Diabetes Mellitus; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Thiophenes | 2022 |
Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Benzhydryl Compounds; Diabetes Mellitus; Glucose; Glucosides; Humans; Male; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH.
Topics: Acyl-CoA Dehydrogenase; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Fatty Acids; Glucosides; Humans; Lipid Metabolism; Liver; Mice; Non-alcoholic Fatty Liver Disease; Proteomics | 2022 |
Rhodiola activates macrophage migration inhibitory factor to alleviate non-alcoholic fatty liver disease.
Topics: Animals; Blood Glucose; Diet, High-Fat; Glucosides; Insulin; Lipid Metabolism; Liver; Macrophage Migration-Inhibitory Factors; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Palmitates; Phenols; Plant Extracts; Rhodiola; RNA, Small Interfering; Saline Solution; Triglycerides | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Cholic Acid; Diet, High-Fat; Fibrosis; Glucosides; Inflammation; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats | 2022 |
Peonidin-3-O-Glucoside from Purple Corncob Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Mitochondrial and Lysosome Functions to Reduce Oxidative Stress and Inflammation.
Topics: Anthocyanins; Fatty Acids, Nonesterified; Glucosides; Inflammation; Liver; Lysosomes; Non-alcoholic Fatty Liver Disease; Oxidative Stress; PPAR alpha; Reactive Oxygen Species; Zea mays | 2023 |
Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress.
Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Endoplasmic Reticulum Stress; Glucosides; Insulin Resistance; Lipogenesis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Glucose; Glucosides; Glutamate Plasma Membrane Transport Proteins; Hypoglycemic Agents; Kidney; Kidney Diseases; Non-alcoholic Fatty Liver Disease; Oryzias; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Progression; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rodentia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules.
Topics: Animals; Apoptosis; Disease Models, Animal; Down-Regulation; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glucosides; Heat-Shock Proteins; Male; Mice; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Thiophenes; Transcription Factor CHOP; Triglycerides | 2019 |
Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
Topics: Animals; Bile Acids and Salts; Diet, High-Fat; Disease Models, Animal; Gastrointestinal Microbiome; Glucosides; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Phenols; Receptors, Cytoplasmic and Nuclear; Triglycerides | 2020 |
Cyanidin-3-O-glucoside improves non-alcoholic fatty liver disease by promoting PINK1-mediated mitophagy in mice.
Topics: Animals; Anthocyanins; Glucosides; Humans; Mice; Mitophagy; Non-alcoholic Fatty Liver Disease; Protein Kinases | 2020 |
2,3,5,4'-tetrahydroxystilbence-2-O-β-D-glucoside attenuates hepatic steatosis via IKKβ/NF-κB and Keap1-Nrf2 pathways in larval zebrafish.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Glucosides; I-kappa B Kinase; Kelch-Like ECH-Associated Protein 1; Lipid Metabolism; NF-E2-Related Factor 2; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Signal Transduction; Stilbenes; Zebrafish; Zebrafish Proteins | 2020 |
Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Benzhydryl Compounds; Diet; Fatty Liver; Fructose; Glucosides; Humans; Inflammation; Interleukin-18; Interleukin-1beta; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Transaminases; Tumor Necrosis Factor-alpha | 2020 |
Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of wogonoside on the inflammatory response and oxidative stress in mice with nonalcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspartate Aminotransferases; Cytokines; Diet, High-Fat; Dose-Response Relationship, Drug; Flavanones; Glucosides; Lipids; Liver; Liver Function Tests; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress | 2020 |
Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
Topics: Animals; Ascites; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Diuresis; Drug Therapy, Combination; Furosemide; Glucosides; Hemodynamics; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Interleukin-17; Interleukin-23; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; RAW 264.7 Cells; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; TOR Serine-Threonine Kinases | 2021 |
Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
Topics: Animals; Aquaporin 2; Body Fluids; Diabetes Mellitus, Type 2; Diuresis; Drinking; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organ Size; Osmolar Concentration; Pioglitazone; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cellular Senescence; Diabetes Mellitus, Experimental; Diet, Western; Disease Models, Animal; Disease Progression; Glucosides; Hepatocytes; Insulin; Liver; Liver Neoplasms; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Receptor, Melanocortin, Type 4; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
Topics: Animals; Antigens, CD; Benzhydryl Compounds; Biopsy; Body Composition; Body Weight; Disease Models, Animal; Glucose; Glucosides; Homeostasis; Insulin Resistance; Lactosylceramides; Lipidomics; Liver; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Triglycerides | 2021 |
Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway.
Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diet, High-Fat; Glucosides; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Oleic Acid | 2021 |
Salidroside Activates the AMP-Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice.
Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Diet, High-Fat; Disease Models, Animal; Glucosides; Hepatocytes; Humans; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Phenols; Primary Cell Culture; Signal Transduction | 2021 |
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Benzyl Alcohols; Diet, High-Fat; Disease Models, Animal; Glucosides; Humans; Lipid Metabolism; Male; Mice; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2021 |
Cyanidin-3-glucoside increases whole body energy metabolism by upregulating brown adipose tissue mitochondrial function.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Anthocyanins; Behavior, Animal; Dietary Supplements; Energy Intake; Energy Metabolism; Gene Expression Regulation; Glucosides; Liver; Locomotion; Male; Mice, Mutant Strains; Microscopy, Electron, Transmission; Mitochondria; Non-alcoholic Fatty Liver Disease; Obesity; Thermotolerance; Uncoupling Protein 1; Up-Regulation; Whole Body Imaging | 2017 |
Anti-steatosis compounds from leaves of Mallotus furetianus.
Topics: Gallic Acid; Glucosides; Hep G2 Cells; Humans; Hydrolyzable Tannins; Mallotus Plant; Non-alcoholic Fatty Liver Disease; Oleic Acid; Plant Leaves | 2018 |
The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.
Topics: Aged; Alanine Transaminase; Diabetes Mellitus, Type 2; Female; Ferritins; Glucosides; Humans; Hypoglycemic Agents; Liver Function Tests; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2; Thiophenes | 2017 |
Cyanidin-3-O-β-glucoside regulates the activation and the secretion of adipokines from brown adipose tissue and alleviates diet induced fatty liver.
Topics: Adipocytes; Adipokines; Adipose Tissue, Brown; Animals; Anthocyanins; Cell Differentiation; Diet, High-Fat; Disease Models, Animal; Glucosides; Hep G2 Cells; Humans; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protective Agents | 2018 |
Paeoniflorin Ameliorates Fructose-Induced Insulin Resistance and Hepatic Steatosis by Activating LKB1/AMPK and AKT Pathways.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Biomarkers; Blood Glucose; Disease Models, Animal; Enzyme Activation; Fructose; Glucosides; Glycogen; Insulin; Insulin Resistance; Lipids; Lipogenesis; Liver; Male; Monoterpenes; Non-alcoholic Fatty Liver Disease; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Salidroside Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via AMPK-Dependent TXNIP/NLRP3 Pathway.
Topics: Animals; Diet, High-Fat; Glucosides; Male; Mice; Non-alcoholic Fatty Liver Disease; Phenols; Rhodiola | 2018 |
Salidroside and Curcumin Formula Prevents Liver Injury in Nonalcoholic Fatty Liver Disease in Rats.
Topics: AMP-Activated Protein Kinases; Animals; Biomarkers; Blood Glucose; Curcumin; Diet, High-Fat; Disease Models, Animal; Drug Combinations; Glucosides; Insulin; Insulin Resistance; Lipid Metabolism; Lipid Peroxidation; Liver; Male; Non-alcoholic Fatty Liver Disease; Phenols; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Asian People; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Humans; Japan; Liver; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Product Surveillance, Postmarketing; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Biopsy; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Waist Circumference | 2020 |
Fat and Fibrosis: Does Empagliflozin Impair the Progression of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Non-alcoholic Fatty Liver Disease | 2020 |
2, 3, 4', 5-tetrahydroxystilbene-2-0-β-d Glycoside Attenuates Age- and Diet-Associated Non-Alcoholic Steatohepatitis and Atherosclerosis in LDL Receptor Knockout Mice and Its Possible Mechanisms.
Topics: Aging; Animals; Aorta; Atherosclerosis; Diet, High-Fat; Glucosides; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Receptors, LDL; Stilbenes | 2019 |
The phytochemical polydatin ameliorates non-alcoholic steatohepatitis by restoring lysosomal function and autophagic flux.
Topics: Animals; Autophagy; Disease Models, Animal; Glucosides; Humans; Lysosomes; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protective Agents; Signal Transduction; Stilbenes | 2019 |
Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).
Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Fish Proteins; Glucosides; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Oryzias; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Lipid Modulating Anti-oxidant Stress Activity of Gastrodin on Nonalcoholic Fatty Liver Disease Larval Zebrafish Model.
Topics: Animals; Antioxidants; Benzyl Alcohols; Disease Models, Animal; Gastrodia; Gene Expression Regulation; Glucosides; Larva; Lipid Metabolism; Non-alcoholic Fatty Liver Disease; Zebrafish | 2019 |
Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
Topics: Animals; Benzhydryl Compounds; Fatty Acids; Gene Expression; Glucose Intolerance; Glucosides; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2019 |
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
Topics: Animals; Benzhydryl Compounds; Glucose; Glucosides; Insulin Glargine; Mice; Non-alcoholic Fatty Liver Disease; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Cyanidin-3-O-β-glucoside protects primary mouse hepatocytes against high glucose-induced apoptosis by modulating mitochondrial dysfunction and the PI3K/Akt pathway.
Topics: Animals; Anthocyanins; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cytochromes c; Diet, High-Fat; Dietary Fats; Fatty Liver; Gene Expression Regulation; Glucose; Glucosides; Hepatocytes; JNK Mitogen-Activated Protein Kinases; Male; Membrane Potential, Mitochondrial; Mice; Mitochondria; Non-alcoholic Fatty Liver Disease; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction | 2014 |
Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
Topics: Amino Acid Transport System ASC; Animals; Body Weight; Carnitine O-Palmitoyltransferase; Cholesterol; Coenzyme A Ligases; Diet, High-Fat; Fenofibrate; Gene Expression Regulation; Glucosides; Humans; Lipid Peroxidation; Lipoproteins, LDL; Liver; Male; Non-alcoholic Fatty Liver Disease; PPAR alpha; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Xanthones | 2015 |
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
Topics: Amino Acids; Animals; Choline Deficiency; Food, Formulated; Glucosides; Hydroxyproline; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Thiophenes; Triglycerides | 2015 |
Paeoniflorin Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice.
Topics: Animals; Blood Glucose; Body Weight; Diet, High-Fat; Glucosides; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Monoterpenes; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; Protective Agents; Transcriptome | 2015 |
Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis.
Topics: Animals; Diet, High-Fat; Flow Cytometry; Glucosides; Inflammation; Intestinal Mucosa; Liver; Male; Microbiota; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Signal Transduction; Stilbenes | 2015 |
Cyanidin 3-glucoside improves diet-induced metabolic syndrome in rats.
Topics: Animals; Anthocyanins; Cardiovascular System; Diet, High-Fat; Dietary Carbohydrates; Dietary Fats; Dietary Supplements; Fruit and Vegetable Juices; Glucosides; Hypertension; Liver; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prunus domestica; Rats; Rats, Wistar | 2015 |
Gastrodin Ameliorates Oxidative Stress and Proinflammatory Response in Nonalcoholic Fatty Liver Disease through the AMPK/Nrf2 Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Antioxidants; Benzyl Alcohols; Gastrodia; Glucosides; Heme Oxygenase-1; Hep G2 Cells; Humans; Inflammation; Male; Malondialdehyde; Mice, Inbred C57BL; NF-E2-Related Factor 2; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phytotherapy; Plant Extracts; Rats, Sprague-Dawley; Reactive Oxygen Species; Superoxide Dismutase; Triglycerides | 2016 |
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hypoglycemic Agents; Insulin Resistance; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Pep
Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Incretins; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Topics: Adipose Tissue; Adult; Animals; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Epididymis; Glucose; Glucosides; Humans; Hyperphagia; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats.
Topics: Administration, Oral; Animals; Antioxidants; Cytochrome P-450 CYP2E1; Diet, High-Fat; Dose-Response Relationship, Drug; Enzyme Repression; Glucosides; Lipid Droplets; Lipid Metabolism; Lipid Peroxidation; Liver; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Oxidoreductases; Phenols; Random Allocation; Rats, Sprague-Dawley; Up-Regulation | 2016 |
Paeoniflorin alleviates non-alcoholic steatohepatitis in rats: Involvement with the ROCK/NF-κB pathway.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Cholesterol; Diet; Disease Models, Animal; Glucosides; Humans; Male; Monoterpenes; NF-kappa B; Non-alcoholic Fatty Liver Disease; Paeonia; Rats; Rats, Sprague-Dawley; Rhizome; rho-Associated Kinases; Signal Transduction; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2016 |
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Topics: Adiposity; Adult; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Japan; Lipotropic Agents; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Severity of Illness Index; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cytochrome P-450 CYP2E1; Diet, High-Fat; Disease Models, Animal; Glucosides; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Monoterpenes; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Reactive Oxygen Species; Signal Transduction | 2017 |
Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-α and SREBP-1c.
Topics: Animals; Anti-Inflammatory Agents; Cholesterol; Diet, High-Fat; Fallopia japonica; Fatty Acid Synthases; Fatty Acids, Nonesterified; Fatty Liver; Glucosides; Lipid Peroxidation; Lipogenesis; Liver; Male; Non-alcoholic Fatty Liver Disease; Protective Agents; Rats; Rats, Sprague-Dawley; Rhizome; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1; Stilbenes; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |